-
Professor Hao Zeng’s Team Publishes in JAMA Oncology: Innovative First-Line Immunotherapy Approach for Advanced FH-Deficient Renal Cell Carcinoma
Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a distinct pathological subtype of RCC characterized by a well-defined driver mutation and high malignancy. In recent years, studies have shown that…
-
AI-Driven Imaging Breakthrough in CAR-T Therapy丨Professor Stephen Schuster on Predicting Efficacy
Challenges of CAR-T-Cell Therapy and the Urgency of Prognostic Prediction Chimeric antigen receptor T-cell (CAR-T) therapy has become one of the standard treatment options for patients with relapsed/refractory large B-cell…
-
Polatuzumab Improves Survival in Relapsed/Refractory DLBCL丨Phase III POLARGO Study Highlights
POLARGO Study Background and Design Polatuzumab vedotin is an antibody-drug conjugate (ADC) targeting CD79b. CD79b is an important component of the B-cell receptor complex and is highly expressed on the…
-
Breakthrough Discovery of LymphoMAPs in Large B-cell Lymphoma丨Professor David Russler-Germain on CAR T Therapy
Challenges and Breakthroughs in Large B-cell Lymphoma Microenvironment Research Large B-cell Lymphoma (LBCL), as a highly heterogeneous malignant hematological tumor, has complex pathogenesis and significant differences in prognosis. Although targeted…
-
New Precision Strategies in DLBCL: Microenvironment Subtyping and Liquid Biopsy Guide Future Therapies
DLBCL Microenvironment Subtyping and Prediction of CAR-T-cell Therapy DLBCL, an aggressive B-cell non-Hodgkin lymphoma, can achieve long-term remission in some patients through standard treatments like R-CHOP, but approximately 30% of…
-
International Dialogue | ASH President-Elect Prof. Robert Negrin Visits Yanda Ludaopei Hospital for a Deep-Dive Conversation with Prof. Lu Peihua on the Future of Cell Therapy
The completion and smooth relocation of the new Hebei Yanda Ludaopei Hospital campus mark a major step forward for the Ludaopei Medical Group’s clinical capacity. On this occasion, internationally renowned hematologist Professor Robert Negrin—Director of the Blood and Marrow Transplantation Program at Stanford University and President-Elect of the American Society of Hematology (ASH)—visited the hospital…
-
SUNMO Study: Mosunetuzumab + Polatuzumab Shows Breakthrough in DLBCL Treatment丨Professor Jason Weston
Treatment Dilemmas and the Emergence of Innovative Solutions For patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who are ineligible for curative treatments such as autologous stem cell…
-
POLARIX Trial: Pola-R-CHP Shows Clear Benefit in Specific DLBCL Subtypes丨Dr. Eleonora Calabretta on the Role of DLBclass
POLARIX Trial: Breaking the Two-Decade Standoff in First-Line DLBCL Treatment Over the past two decades, numerous clinical trials have attempted to improve the prognosis of DLBCL patients by adding new…
Connecting Medical Expertise through Media